nach oben

Irish Journal of Medical Science (1971 -)

Erschienen in:

17.06.2022 | COVID-19 | Original Article

The presence of symptoms within 6 months after COVID-19: a single-center longitudinal study

verfasst von: Ahmet Naci Emecen, Salih Keskin, Oyku Turunc, Ahmet Furkan Suner, Neslisah Siyve, Ecem Basoglu Sensoy, Fatih Dinc, Oguz Kilinc, Vildan Avkan Oguz, Serdar Bayrak, Belgin Unal

Erschienen in: Irish Journal of Medical Science (1971 -) | Ausgabe 2/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

Characterizing the post-COVID health conditions is helpful to direct patients to appropriate healthcare.

Aims

To describe the presence of symptoms in COVID-19 patients within 6 months after diagnosis and to investigate the associated factors in terms of reporting symptoms.

Methods

Data of DEU-COVIMER (a telephone interview-based COVID-19 follow-up center established in a tertiary care hospital) was analyzed for SARS-CoV-2 RNA positive participants aged ≥ 18 years from November 1st, 2020, to May 31st, 2021. Symptom frequencies were stratified by demographic and clinical characteristics at one, three, and 6 months after diagnosis. With the patients who had symptoms at baseline, generalized estimating equations were applied to identify the factors associated with reporting of symptoms.

Results

A total of 5610 patients agreed to participate in the study. Symptom frequency was 37.2%, 21.8%, and 18.2% for the first, third, and sixth months. Tiredness/fatigue, muscle or body aches, and dyspnea/difficulty breathing were the most common symptoms in all time frames. In multivariate analysis, older age, female gender (odds ratio OR 1.74, 95% confidence interval 1.57–1.93), bad economic status (OR 1.37, 1.14–1.65), current smoking (OR 1.15, 1.02–1.29), being fully vaccinated before COVID-19 (OR 0.53, 0.40–0.72), having more health conditions (≥ 3 conditions, OR 1.78, 1.33–2.37), having more symptoms (> 5 symptoms, OR 2.47, 2.19–2.78), and hospitalization (intensive care unit, OR 2.18, 1.51–3.14) were associated with reporting of symptoms.

Conclusions

This study identifies risk factors for patients who experience post-COVID-19 symptoms. Healthcare providers should appropriately allocate resources prioritizing the patients who would benefit from post-COVID rehabilitation.

Callard F, Perego E (2021) How and why patients made Long Covid. Soc Sci Med 268:113426. https://doi.org/10.1016/j.socscimed.2020.113426CrossRefPubMedPubMedCentral

Alwan NA, Johnson L (2021) Defining long COVID: going back to the start. Med N Y N 2:501–504. https://doi.org/10.1016/j.medj.2021.03.003CrossRef

Carfì A, Bernabei R, Landi F et al (2020) Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent symptoms in patients after acute COVID-19. JAMA 324:603–5. https://doi.org/10.1001/jama.2020.12603CrossRefPubMedPubMedCentral

Huang C, Huang L, Wang Y et al (2021) 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. The Lancet Elsevier 397:220–232. https://doi.org/10.1016/S0140-6736(20)32656-8CrossRef

Nehme M, Braillard O, Alcoba G et al (2021) COVID-19 symptoms: longitudinal evolution and persistence in outpatient settings. Ann Intern Med 174:723–725. https://doi.org/10.7326/M20-5926CrossRefPubMed

Petersen MS, Kristiansen MF, Hanusson KD et al (2021) Long COVID in the Faroe Islands: a longitudinal study among nonhospitalized patients. Clin Infect Dis Off Publ Infect Dis Soc Am 73:e4058-63. https://doi.org/10.1093/cid/ciaa1792CrossRef

Chopra V, Flanders SA, O’Malley M, Malani AN (2021) Prescott HC. Sixty-day outcomes among patients hospitalized with COVID-19. American College of Physicians. Ann Intern Med 174:576–8. https://doi.org/10.7326/M20-5661CrossRefPubMed

Groff D, Sun A, Ssentongo AE et al (2021) Short-term and long-term rates of postacute sequelae of SARS-CoV-2 ınfection: a systematic review. JAMA Netw Open 4:e2128568. https://doi.org/10.1001/jamanetworkopen.2021.28568CrossRefPubMedPubMedCentral

Lopez-Leon S, Wegman-Ostrosky T, Perelman C et al (2021) More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep. Nature Publishing Group 11:16144. https://doi.org/10.1038/s41598-021-95565-8CrossRef

10.

Fernández-de-las-Peñas C, Palacios-Ceña D, Gómez-Mayordomo V et al (2021) Defining post-COVID symptoms (post-acute COVID, long COVID, persistent post-COVID): an ıntegrative classification. Int J Environ Res Public Health. Multidisciplinary Digital Publishing Institute 18:2621. https://doi.org/10.3390/ijerph18052621

11.

Tenforde MW, Kim SS, Lindsell CJ et al (2020) Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network — United States, March–June 2020. MMWR Morb Mortal Wkly Rep 69:993–8. https://doi.org/10.15585/mmwr.mm6930e1

12.

Soriano JB, Murthy S, Marshall JC et al (2021) A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis S1473309921007039. https://doi.org/10.1016/S1473-3099(21)00703-9

13.

Sigfrid L, Cevik M, Jesudason E et al (2021) What is the recovery rate and risk of long-term consequences following a diagnosis of COVID-19? A harmonised, global longitudinal observational study protocol. BMJ Open 11:e043887. https://doi.org/10.1136/bmjopen-2020-043887CrossRefPubMed

14.

Evans RA, McAuley H, Harrison EM et al (2021) Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. Lancet Respir Med 9:1275–1287. https://doi.org/10.1016/S2213-2600(21)00383-0CrossRefPubMedPubMedCentral

15.

Sudre CH, Murray B, Varsavsky T et al (2021) Attributes and predictors of long COVID. Nat Med Nature Publishing Group 27:626–631. https://doi.org/10.1038/s41591-021-01292-yCrossRef

16.

Klein H, Asseo K, Karni N et al (2021) Onset, duration and unresolved symptoms, including smell and taste changes, in mild COVID-19 infection: a cohort study in Israeli patients. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis S1198–743X(21)00083–5. https://doi.org/10.1016/j.cmi.2021.02.008

17.

Whitaker M, Elliott J, Chadeau-Hyam M et al (2022) Persistent COVID-19 symptoms in a community study of 606,434 people in England. Nat Commun 13(1):1957. https://doi.org/10.1038/s41467-022-29521-zCrossRefPubMedPubMedCentral

18.

Williamson EJ, Walker AJ, Bhaskaran K et al (2020) Factors associated with COVID-19-related death using OpenSAFELY. Nature Nature Publishing Group 584:430–436. https://doi.org/10.1038/s41586-020-2521-4CrossRef

19.

Dessie ZG, Zewotir T (2021) Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients. BMC Infect Dis 21:855. https://doi.org/10.1186/s12879-021-06536-3CrossRefPubMedPubMedCentral

20.

Booth A, Reed AB, Ponzo S, Yassaee A, Aral M, Plans D et al (2021) Population risk factors for severe disease and mortality in COVID-19: A global systematic review and meta-analysis. PLoS ONE. Public Library of Science 16:e0247461. https://doi.org/10.1371/journal.pone.0247461

21.

Sykes DL, Holdsworth L, Jawad N, Gunasekera P, Morice AH, Crooks MG (2021) Post-COVID-19 symptom burden: what is long-COVID and how should we manage ıt? Lung 199:113–119. https://doi.org/10.1007/s00408-021-00423-zCrossRefPubMedPubMedCentral

22.

Mahmud R, Rahman MM, Rassel MA, Monayem FB, Sayeed SKJB, Islam MS et al (2021) Post-COVID-19 syndrome among symptomatic COVID-19 patients: A prospective cohort study in a tertiary care center of Bangladesh. PLoS ONE. Public Library of Science 16:e0249644. https://doi.org/10.1371/journal.pone.0249644

23.

Kokturk N, Babayigit C, Kul S et al (2021) The predictors of COVID-19 mortality in a nationwide cohort of Turkish patients. Respir Med 183:106433. https://doi.org/10.1016/j.rmed.2021.106433CrossRefPubMedPubMedCentral

24.

Gülsen A, Yigitbas BA, Uslu B et al (2020) The effect of smoking on COVID-19 Symptom severity: systematic review and meta-analysis. Pulm Med e7590207. https://doi.org/10.1155/2020/7590207

25.

Ismail N, Hassan N, Abd Hamid MHN et al (2022) Association of smoking and severity of COVID-19 infection among 5,889 patients in Malaysia: a multi-center observational study. Int J Infect Dis 116:189–196. https://doi.org/10.1016/j.ijid.2022.01.011CrossRefPubMedPubMedCentral

26.

Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK - Office for National Statistics (2022) https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/3march2022. Assessed: 06 April 2022

27.

Antonelli M, Penfold RS, Merino J et al (2022) Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis Elsevier 22:43–55. https://doi.org/10.1016/S1473-3099(21)00460-6CrossRef

28.

Tenforde MW, Self WH, Adams K et al (2021) Association between mRNA vaccination and COVID-19 hospitalization and disease severity. JAMA 326:2043–2054. https://doi.org/10.1001/jama.2021.19499CrossRefPubMed

29.

Agrawal U, Katikireddi SV, McCowan C et al (2021) COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2·57 million people in Scotland (EAVE II): a prospective cohort study. Lancet Respir Med Elsevier 9:1439–1449. https://doi.org/10.1016/S2213-2600(21)00380-5CrossRef

30.

Bahl A, Johnson S, Maine G et al (2021) Vaccination reduces need for emergency care in breakthrough COVID-19 infections: a multicenter cohort study. Lancet Reg Health Am 4:100065. https://doi.org/10.1016/j.lana.2021.100065CrossRefPubMedPubMedCentral

31.

Butt AA, Nafady-Hego H, Chemaitelly H et al (2021) Outcomes among patients with breakthrough SARS-CoV-2 ınfection after vaccination. Int J Infect Dis Elsevier 110:353–358. https://doi.org/10.1016/j.ijid.2021.08.008CrossRef

Titel: The presence of symptoms within 6 months after COVID-19: a single-center longitudinal study
verfasst von: Ahmet Naci Emecen
Salih Keskin
Oyku Turunc
Ahmet Furkan Suner
Neslisah Siyve
Ecem Basoglu Sensoy
Fatih Dinc
Oguz Kilinc
Vildan Avkan Oguz
Serdar Bayrak
Belgin Unal
Publikationsdatum: 17.06.2022
Verlag: Springer International Publishing
Schlagwort: COVID-19
Erschienen in: Irish Journal of Medical Science (1971 -) / Ausgabe 2/2023
Print ISSN: 0021-1265
Elektronische ISSN: 1863-4362
DOI: https://doi.org/10.1007/s11845-022-03072-0

Cost and public reimbursement of cancer medicines in the UK and the Republic of Ireland

Original Article

Evaluation of the relationship between theory of mind relating to cognitive performance and post-traumatic stress disorder in Syrian refugee amputees living in Turkey

Original Article

Contemporary trends can be revealed in an enquiry of presentations at a surgical symposium

Original Article

Gene expression and transcriptional regulation driven by transcription factors involved in congenital heart defects

Original Article

Incidence of SARS-CoV-2 re-infection in anti-nucleocapsid IgG-positive healthcare workers: a prospective cohort study

Original Article

Advanced clinical prioritisation in an Irish, tertiary, chronic pain management service: an audit of outcomes

Original Article

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Chemoembolisation bei HCC frühzeitig mit Checkpoint-Inhibitor kombinieren?

24.01.2025
Hepatozelluläres Karzinom
Nachrichten

Beim hepatozellulären Karzinom scheint sich eine neue Therapieoption abzuzeichnen: In zwei randomisierten Studien ließ sich das progressionsfreie Überleben mit der Kombination aus Chemoembolisation, Checkpoint-Inhibitor und antiangiogener Therapie signifikant verbessern.

Antikörper-Wirkstoff-Konjugat hält Brusttumoren langfristig in Schach

24.01.2025
Mammakarzinom
Nachrichten

Erreichen Frauen mit HER2-positivem Mammakarzinom nach einer neoadjuvanten Therapie keine Komplettremission, bietet eine Therapie mit Trastuzumab Emtansin langfristig Vorteile: Die Sterberate ist im Vergleich zu einer Trastuzumab-Therapie um ein Drittel reduziert.

Studie zur HIFU bei Prostatakrebs lässt viele Fragen offen

22.01.2025
Prostatakarzinom
Nachrichten

Führt eine HIFU-Ablation beim Prostatakarzinom im Vergleich mit einer radikalen Prostatektomie zu ähnlichen onkologischen, aber besseren funktionalen Ergebnissen? Interimsdaten der französischen HIFI-Studie sind uneindeutig. In einem Kommentar zur Studie werden zumindest drei allgemeine Erkenntnisse herausgearbeitet.

Leitlinienkonformes Management thermischer Verletzungen

22.01.2025
Verbrennung
Nachrichten

Thermische Verletzungen gehören zu den schwerwiegendsten Traumen und hinterlassen oft langfristige körperliche und psychische Spuren. Die aktuelle S2k-Leitlinie „Behandlung thermischer Verletzungen im Kindesalter (Verbrennung, Verbrühung)“ bietet eine strukturierte Übersicht über das empfohlene Vorgehen.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Jetzt 10 CME-Punkte sammeln

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

The presence of symptoms within 6 months after COVID-19: a single-center longitudinal study